SERA PROGNOSTICS, INC.
Sera Prognostics is a women’s health company that develops and commercializes blood-based biomarker tests and predictive analytics products and services for pregnant women, their physicians and health care payers. Its first commercial product, the PreTRM test, is a non-invasive blood test for women carrying a single fetus, administered during weeks 18 through 20 of gestation to predict the risk of spontaneous preterm birth before 37 weeks. Sera Prognostics uses a proprietary platform combining pregnancy specimen biobanks, proteomics, mass spectrometry, immunoassays and bioinformatics to discover and validate tests. It seeks payment through third-party reimbursement, including health systems, physician networks and insurance payers, as well as consumer-payment models for some products. The company is also developing tests and analytics for other pregnancy-related conditions, including preeclampsia and gestational diabetes. Sera Prognostics is headquartered in Salt Lake City, Utah.
Sera Prognostics (SERA) reported Q3 EPS of -$0.16, matching estimates, but revenue of $40K missed the $71.05K consensus. The stock is down 2.42% over 3 months and 34.63% over 12 months. InvestingPro rates its financial health as 'fair performance'.
Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER Salt Lake City – August 19, 2026 – Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker informatio
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning SERA (SERA PROGNOSTICS, INC.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent SERA coverage spans earnings, corporate actions and financial news.
In the last 30 days, SERA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($16K). The most active reporter was Inglis Tiffany Eul Davis, Chief Medical Officer, with 1 filing.
Revenue miss suggests weaker demand and may pressure the stock.
Modest revenue growth but widening loss; cash balance suggests runway but highlights need for commercial scale.
New CFO hire may affect leadership stability and compensation outlook.
New CFO may improve capital allocation and investor relations, potentially supporting stock stability.
Near-term focus is Medicaid contracting and provider activation, with utilization scaling expected into early 2027; clinical and CE-marking milestones support longer-dated adoption.
AlphAI scores every news story that mentions SERA with an AI model for sentiment and relevance, and aggregates insider trades from SERA PROGNOSTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sera Prognostics (SERA) reported Q3 EPS of -$0.16, matching estimates, but revenue of $40K missed the $71.05K consensus. The stock is down 2.42% over 3 months and 34.63% over 12 months. InvestingPro rates its financial health as 'fair performance'.
Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER Salt Lake City – August 19, 2026 – Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker informatio
Sera Prognostics Inc. (SERA) appointed Scott Gleason as Chief Financial Officer, effective August 31, 2026. Gleason has 25 years of healthcare and diagnostics experience, previously serving as CFO at LarmorBio and NX Prenatal. Austin Aerts, current CFO, will transition to an advisory role. Gleason's expertise is expected to support Sera's commercial growth and execution of its PreTRM® Test, which predicts preterm birth risk.
Sera Prognostics (NASDAQ:SERA) reported Q2 call highlights on Illinois Medicaid coverage for its proteomic PreTRM blood test and related care-management. Management said provider registration may take months to a year, payer contracting 6 to 9 months, and expects limited Illinois penetration in 2026. It cited PRIME results, including a 22% NICU admission reduction, and outlined expanding payer programs and CE-marking plans.
Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t
Sera Prognostics (Nasdaq: SERA) reported a PRIME trial subgroup analysis in first-time pregnancies (n=1,783). According to the company, PreTRM Test-guided care reduced NICU admissions by 22% versus routine care and lowered severe composite morbidity (6.4% vs 9.1%). The study also cited 28 screenings to prevent one NICU admission.
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001534969 0001534969 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
Whetstone Capital Advisors, LLC and David Atterbury have amended their stake in Sera Prognostics (NASDAQ: SERA), now reporting beneficial ownership of 3,306,889 shares of Class A Common Stock, which represents 8.6% of the class. This update was disclosed in a Schedule 13G/A filing with the SEC, indicating shared voting and dispositive power over these shares. The filing, signed on May 1, 2026, reflects a passive investment and transparency regarding their holdings.
